Targeted removal of (putatively toxic) aggregated ApoE4 with an antibody, is anticipated to: (i) reduce amyloid plaque and CAA, and (ii) improve vascular function, and is expected to be most beneficial in APOE4/4 patients with AD stages 3 & 4. The gene discussed is APOE; the disease is Alzheimer disease.